Encouraging signs for Takeda's dengue vaccine program

Osaka, Japan-based Takeda Pharmaceutical (TYO: 4502) has released interim data from a Phase II trial into its dengue vaccine candidate TAK-003. The full analysis has been published in The Lancet.

The data showed two doses of the vaccine candidate induced antibody responses against all four types of dengue virus in a large population aged 2-17. The company said that no safety concerns were observed.

“The levels of immunogenicity induced by TAK-003 against all four dengue serotypes, even in seronegative participants, are encouraging because seropositivity after vaccination may be an important measure of vaccine performance,” said Xavier Sáez-Llorens, director of clinical research at the Panama Children’s Hospital.